Gabapentin Capsule
Product Images NDC 71335-2773

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 71335-2773). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Fig-1 (Gabapentin Fig1)

A mathematical formula illustrating the calculation for creatinine clearance (CLCr), showing the relationship between age, weight, serum creatinine levels, and a gender adjustment factor for females. This formula is typically used in clinical contexts to estimate kidney function.*

FDA Label Image

Figure 1 (Gabapentin Fig2)

A line graph comparing the mean pain scores over 8 weeks between two groups: placebo and Gabapentin 3600 mg/day. The graph is divided into a 4-week dose titration period and a 4-week fixed dose period, showing a decrease in mean pain scores for the Gabapentin group over time compared to the placebo group.*

FDA Label Image

Figure 2 (Gabapentin Fig3)

Line graph depicting mean pain scores over a 7-week period comparing placebo, gabapentin 1800 mg/day, and gabapentin 2400 mg/day. The x-axis represents weeks, including a 3-week dose titration period and a 4-week fixed dose period. Pain scores on the y-axis decrease more for gabapentin groups than placebo over time.*

FDA Label Image

Figure 3 (Gabapentin Fig4)

A bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' displaying data from two studies. The vertical axis shows percentage responders from 0% to 100%. Study 1 compares placebo (PBO) with Gabapentin (GBP) 3600 mg, showing approximately 12% responders for placebo and 29% for GBP. Study 2 compares placebo with GBP 1800 mg and GBP 2400 mg, showing about 14% responders for placebo and 32% and 34% respectively for the GBP doses.*

FDA Label Image

Fig-5 (Gabapentin Fig5)

A scatter plot showing percentage difference on the vertical axis and daily dose in milligrams on the horizontal axis. Data points represent three studies labeled as STUDY a, STUDY b, and STUDY c, plotted for daily doses of approximately 600, 900, 1200, and 1800 mg. Each study uses different symbols and shades for distinction.*

FDA Label Image

Chemical Structure (Gabapentin Str)

Chemical structure diagram of gabapentin, showing a cyclohexane ring attached to an amino group (CH2NH2) and a carboxymethyl group (CH2CO2H). This depicts the molecular framework of the active ingredient gabapentin.*

FDA Label Image

Label (Lbl713352773)

Gabapentin Capsules USP 400 mg label showing NDC 71335-2773-1. The label indicates the package contains 90 capsules and is repackaged by Bryant Ranch Prepack, Burbank, CA, with manufacturing by Aurobindo Pharma Limited. Storage instructions and a QR code for package insert are also visible.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.